<div id="readability-page-1"><div>                     <div><h2>Key Points</h2><ul>   <li><strong>Insider sale:</strong> Director Jula Inrig sold 20,000 shares at an average $45.00 (total $900,000) under a Rule 10b5‑1 plan to cover tax withholding, reducing her stake by 15.21% to 111,473 shares (≈$5.02M).</li>   <li><strong>Broader insider selling:</strong> Multiple executives — including the CEO — have recently sold shares (many via pre‑arranged plans), a volume of transactions that could create short‑term selling pressure or investor concern.</li>   <li><strong>Fundamentals and financing:</strong> Travere reported an EPS beat (Q1 EPS $0.05 vs. -$0.24) with revenue up 55.6% YoY, prompting several analyst price‑target upgrades, while the company priced an upsized $475M convertible senior notes offering (potential liquidity boost but dilution risk if converted).</li> </ul></div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/travere-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MTEwNzEzNDU1Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/travere-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MTEwNzEzNDU1Mg"/>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 2,076 shares of the company's stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total transaction of $91,240.20. Following the transaction, the insider owned 105,211 shares in the company, valued at approximately $4,624,023.45. This trade represents a 1.93% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.</p><h2>Travere Therapeutics Stock Performance</h2><ul><li>3 Under-the-Radar Healthcare Companies</li></ul><p>TVTX opened at $44.70 on Thursday. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16. The company has a market cap of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. The firm's 50-day moving average price is $32.59 and its 200-day moving average price is $32.83. </p><hr/><hr/><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm had revenue of $127.20 million for the quarter, compared to the consensus estimate of $136.23 million. During the same quarter in the prior year, the company posted ($0.47) earnings per share. The company's revenue for the quarter was up 55.6% compared to the same quarter last year.  As a group, equities analysts anticipate that  Travere Therapeutics, Inc. will post -0.16 EPS for the current fiscal year. </p><h2>Institutional Investors Weigh In On Travere Therapeutics</h2><ul><li>Travere Therapeutics Still On The Rise After Encouraging Data </li></ul><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Emerald Advisers LLC boosted its stake in  Travere Therapeutics by 2.6% during the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock worth $51,308,000 after purchasing an additional 55,407 shares during the last quarter.  Palisades Investment Partners LLC acquired a new stake in  Travere Therapeutics during the 4th quarter worth $5,264,000.  Essex Investment Management Co. LLC acquired a new stake in  Travere Therapeutics during the 3rd quarter worth $3,872,000.  Lisanti Capital Growth LLC acquired a new stake in  Travere Therapeutics during the 3rd quarter worth $3,095,000.  Finally, Apis Capital Advisors LLC acquired a new stake in  Travere Therapeutics during the 3rd quarter worth $3,967,000. </p><h2>Key Stories Impacting Travere Therapeutics</h2><p>Here are the key news stories impacting Travere Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>TD Cowen raised its price target to $60 and keeps a &#34;buy&#34; rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. <i></i><span>Article Title</span></li>    <li><span>Positive Sentiment: </span>Wells Fargo raised its price target to $50 and moved to an &#34;overweight&#34; rating — another bullish analyst signal adding demand. <i></i><span>Article Title</span></li>    <li><span>Positive Sentiment: </span>Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year‑over‑year, providing fundamental support for the analyst upgrades and investor optimism. <span>No link</span></li>    <li><span>Neutral Sentiment: </span>Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. <i></i><span>Article Title</span></li>    <li><span>Neutral Sentiment: </span>HC Wainwright slightly trimmed long‑term EPS forecasts (FY2027–FY2030) but maintains a &#34;Buy&#34; rating and a $57 target — small model tweaks that didn’t remove analyst support. <span>No link</span></li>    <li><span>Neutral Sentiment: </span>Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. <i></i><span>Earnings Call Transcript</span></li>    <li><span>Negative Sentiment: </span>Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre‑arranged Rule 10b5‑1 plans and to cover tax withholding on awards, the volume (notably the CEO's 22,500‑share sale) can create short‑term selling pressure or investor concern. Example SEC filing: <i></i><span>CEO Form 4</span></li> </ul><h2>Analyst Upgrades and Downgrades</h2><p>Several equities analysts recently weighed in on the stock. Citigroup increased their price target on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday. Piper Sandler upgraded shares of Travere Therapeutics from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and set a $49.00 price target on the stock in a report on Tuesday, April 14th. Wall Street Zen downgraded shares of Travere Therapeutics from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, February 21st. JPMorgan Chase &amp; Co. dropped their price objective on shares of Travere Therapeutics from $44.00 to $41.00 and set an &#34;overweight&#34; rating on the stock in a research note on Wednesday, March 25th. Finally, Guggenheim raised their price objective on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, April 24th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has issued  a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $47.83.</p><p><b>View Our Latest Report on Travere Therapeutics</b></p><h2>Travere Therapeutics Company Profile</h2><p> (Get Free Report)</p><p>Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.  </p><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p><h2>Read More</h2><ul><li>Five stocks we like better than Travere Therapeutics</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Travere Therapeutics?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Travere Therapeutics and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260220101326_pushjb4-before.png"/></p><div><p>SpaceX eyes a 1.75 trillion valuation - here's what to know</p><p>Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODk0OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/trump-2-0-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="593" original-src="https://imageproxy.pbkrs.com/https://www.advantagegold.com/wp-content/uploads/2025/05/trump-2-0-1.png"/></p><div><p>Iran's New Leader Just Said Something That Should Terrify Every American</p><p>Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...</p><p><span>American Alternative</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODkwMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODkwMg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420142948_pushiphone-410311640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260420142948_pushiphone-410311640.jpg"/></p><div><p>Your book attached</p><p>Your Download Link (Expiring)  If you still haven't downloaded the free Simple Options Trading For Beginners...</p><p><span>Profits Run</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTAwNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTAwNA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/03/Screenshot-2026-03-24-150248-1.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="250" height="250" original-src="https://imageproxy.pbkrs.com/https://assets.stansberryresearch.com/uploads/sites/4/2026/03/Screenshot-2026-03-24-150248-1.png"/></p><div><p>My feud with Zohran Mamdani</p><p>Emmy-winning analyst releases his next big story  Whitney Tilson shocked the nation on 60 Minutes when he ac...</p><p><span>Stansberry Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODU5Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODU5Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260406130341_pushstock-market-6695489640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20260406130341_pushstock-market-6695489640.jpg"/></p><div><p>The $1.75T &#34;Backdoor&#34; ticker (NOT Starlink)</p><p>When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...</p><p><span>Behind the Markets</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA2MA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xOTA2MA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://dkwegfj7whlol.cloudfront.net/copypasta/images/Nate_Warning.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="550" height="309" original-src="https://imageproxy.pbkrs.com/https://dkwegfj7whlol.cloudfront.net/copypasta/images/Nate_Warning.jpg"/></p><div><p>Sell 99% of Your Stocks, Do THIS Instead…</p><p>Millionaire Trader Exposes: &#34;The Single Stock Income Plan&#34;   With over 6,000 stocks on the market to choose ...</p><p><span>The Oxford Club</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODgzOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODgzOQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://mqebooks.s3.amazonaws.com/retirement/retire-guide-2-dn.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="540" height="500" original-src="https://imageproxy.pbkrs.com/https://mqebooks.s3.amazonaws.com/retirement/retire-guide-2-dn.png"/></p><div><p>Trade this between 9:30 and 10:45 am EST</p><p>The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...</p><p><span>Base Camp Trading</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzUzMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNzUzMA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/images/lies-450.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="450" height="156" original-src="https://imageproxy.pbkrs.com/https://files.admin.sovereignsociety.com/images/lies-450.png"/></p><div><p>Iran War Shock: What I Was Told In That Private Meeting</p><p>You’re Being LIED To About The Iran War  Forget EVERYTHING you’ve heard about the Iran war.  Especially th...</p><p><span>Banyan Hill Publishing</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODcyOQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xODcyOQ"/></p></div></div></div>                     </div>                 </div></div>

TVTX

<p>Elizabeth Reed, an insider at Travere Therapeutics, sold 2,076 shares of the company's stock at an average price of $43.95, totaling $91,240.20. This sale, executed under a Rule 10b5-1 trading plan, reduced her stake by 1.93%. The company recently reported a Q1 EPS of $0.05, beating estimates, and a 55.6% revenue increase year-over-year. Multiple executives have sold shares, raising concerns about short-term selling pressure. Analysts have upgraded price targets following positive earnings, with TD Cowen raising its target to $60 and Wells Fargo to $50.</p>

Elizabeth Reed Sells 2,076 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock